Lipocine Inc.
LPCN · Nasdaq · United States
Share price · LPCN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LPCN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026-8.8%
Nothing announced by LPCN that day or the session before.
- 9 Oct 2026-10.9%
Nothing announced by LPCN that day or the session before.
- 8 Oct 2026-12.3%
- 22 Sep 2026-3.6%
Nothing announced by LPCN that day or the session before.
- 2 Apr 2026-77.8%
- 1 Apr 2026+15.8%
Nothing announced by LPCN that day or the session before.
- 13 Jan 2026+15.9%
- 12 Jan 2026+12.7%
- 31 Dec 2025+22.2%
Nothing announced by LPCN that day or the session before.
- 29 Dec 2025+20.3%
Nothing announced by LPCN that day or the session before.
Share of unusual movement by asset
For each asset, the share of LPCN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Androgen receptor (AR)Small molecule | Male Hypogonadism Hypogonadism |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $2.3M | $2.1M | $2.6M+ $19M short-term inv. | $0.7M-$1.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.2M | $2.0M | $5.0M+ $18M short-term inv. | $2.6M-$3.0M operating cash flow | report ↗ |
| 2026-Q1 | $0.1M | $2.8M | $5.0M+ $20M short-term inv. | $3.7M-$2.3M operating cash flow | report ↗ |
| 2025-Q3 | $0.1M | $2.7M | $3.9M+ $11M short-term inv. | $3.2M-$3.0M operating cash flow | report ↗ |
| 2025-Q2 | $0.6M | $2.1M | $6.0M+ $12M short-term inv. | $2.2M-$1.9M operating cash flow | report ↗ |
| 2025-Q1 | $0.1M | $1.1M | $3.4M+ $16M short-term inv. | $1.9M-$2.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.6M | $3.7M+ $16M short-term inv. | $2.2M-$2.8M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $1.9M | $5.5M+ $17M short-term inv. | $3.1M-$2.5M operating cash flow | report ↗ |
| 2024-Q1 | $7.6M | $2.8M | $3.1M+ $22M short-term inv. | —$2.4M operating cash flow | report ↗ |
| 2023-Q3 | -$3.1M | $2.9M | $4.1M+ $20M short-term inv. | $6.7M-$2.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.5M | $5.0M+ $21M short-term inv. | $3.5M-$3.3M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $3.1M | $4.8M+ $24M short-term inv. | $3.9M-$3.9M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.1M | $2.4M+ $32M short-term inv. | $2.4M-$3.2M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.9M | $5.0M+ $32M short-term inv. | $2.6M-$3.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.9M | $5.7M+ $36M short-term inv. | $3.5M-$3.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.4M | $4.5M+ $34M short-term inv. | $3.1M-$7.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.0M | $8.6M | $5.2M+ $9.7M short-term inv. | $2.4M-$9.8M operating cash flow | report ↗ |
Lipocine reported full-year 2025 revenue of $1.98M, down 82.3% YoY, with R&D spend of $8.58M, up 16.7% YoY. The company recorded a net loss of $9.63M, or $1.69 per diluted share, and ended the year with $5.21M in cash and equivalents; total cash, equivalents and marketable investment securities were $14.9M as of December 31, 2025, and approximately $24.7M as of March 6, 2026 following an ATM offering.
Pipeline updates included completion of the last patient visit in the Phase 3 study of LPCN 1154 for postpartum depression, with top-line results expected in early April 2026 and a potential U.S. NDA submission in mid-2026. The company also highlighted progress on LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management, and disclosed ongoing TLANDO commercialization partnerships, including a new license and supply agreement with Aché in Brazil.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $11M | $7.3M | $6.2M+ $15M short-term inv. | —-$1.2M operating cash flow | report ↗ |
| 2023-FY | -$2.9M | $10M | $4.8M+ $17M short-term inv. | $4.1M-$12M operating cash flow | report ↗ |
| 2022-FY | $0.5M | $8.6M | $3.1M+ $29M short-term inv. | $2.7M-$12M operating cash flow | report ↗ |
| 2021-FY | $16M | $7.7M | $3.0M+ $42M short-term inv. | $0.2M-$4.4M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($596K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Patel Mahesh V. · director, Chief Executive Officer | Open-market purchase | 25,000 | $1.60 | $40K | Form 4 |
| 2026-11-12 | Patel Mahesh V. · director, Chief Executive Officer | Open-market purchase | 25,000 | $1.58 | $39K | Form 4 |
| 2026-09-30 | Higuchi John W. · director | Open-market purchase | 15,970 | $2.23 | $36K | Form 4 |
| 2026-09-29 | Higuchi John W. · director | Open-market purchase | 9,037 | $2.15 | $19K | Form 4 |
| 2026-09-28 | Higuchi John W. · director | Open-market purchase | 12,561 | $2.16 | $27K | Form 4 |
| 2026-08-03 | Grissinger Michael · director | Award / grant (derivative) | 2,000 | $2.11 | $4K | Form 4 |
| 2026-06-29 | Patel Mahesh V. · director, Chief Executive Officer | Award / grant (derivative) | 52,781 | $2.49 | $131K | Form 4 |
| 2026-06-03 | Ono Richard Dana · director | Award / grant (derivative) | 1,764 | $2.19 | $4K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 47 reporting institutions held 3.3M shares ($26.2M, 29.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Ikarian Capital, LLC | 508,556 | $4.1M |
| 2 | Squadron Capital Management LLC | 450,000 | $3.6M |
| 3 | STEMPOINT CAPITAL LP | 320,840 | $2.6M |
| 4 | Eversept Partners, LP | 294,989 | $2.4M |
| 5 | Rosalind Advisors, Inc. | 221,616 | $1.8M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 200,668 | $1.6M |
| 7 | AIGH Capital Management LLC | 200,000 | $1.6M |
| 8 | BOOTHBAY FUND MANAGEMENT, LLC | 140,487 | $1.1M |
| 9 | Seven Fleet Capital Management LP | 124,942 | $998K |
| 10 | Birchview Capital, LP | 111,786 | $893K |
| 11 | BlackRock, Inc. | 89,272 | $713K |
| 12 | Mink Brook Asset Management LLC | 66,812 | $534K |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 63,135 | $505K |
| 14 | Exome Asset Management LLC | 60,861 | $486K |
| 15 | DIADEMA PARTNERS LP | 50,000 | $400K |